[Cancer therapy using intermittent high doses of cytostatics].
The results of intermittent high-dose-therapy, especially with Doxorubicin and Amethopterin, are encouraging, particularly, against those malignant tumors which were difficult to influence until now. The damage to normal tissue and especially the therapy-limiting cumulative toxicity, seem to be lower if compared with the continuous low-dose-treatment because of the possibility for complete recovery of normal tissue during therapy-free intervals. Correlations between tumor, normal tissue and cytotoxic agent are discussed on the basis of cellkinetic findings to contribute to a better understanding of the way of action of a high-dose-therapy.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013964:Thyroid Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents
Zur Karzinom-Therapie mit intermittierender Hoch-Dosis-Zytostatika-Behandlung